Vanda Pharmaceuticals (VNDA) Net Cash Flow Growth (3y) (2013 - 2026)
Vanda Pharmaceuticals (VNDA) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Vanda Pharmaceuticals | 310.98 Mn | 108.67 Mn | 48.56 Mn | -28.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.87% |
| Dec 31, 2025 | -44.25% |
| Sep 30, 2025 | -6.46% |
| Jun 30, 2025 | -52.17% |
| Mar 31, 2025 | -14.16% |
| Dec 31, 2024 | 6.99% |
| Sep 30, 2024 | 28.20% |
| Jun 30, 2024 | -14.26% |
| Mar 31, 2024 | -43.55% |
| Dec 31, 2023 | -139.50% |
| Sep 30, 2023 | 42.07% |
| Jun 30, 2023 | -105.89% |
| Mar 31, 2023 | 122.57% |
| Dec 31, 2022 | 146.90% |
| Sep 30, 2022 | -6.89% |
| Jun 30, 2022 | -39.62% |
| Mar 31, 2022 | 36.80% |
| Dec 31, 2021 | 87.33% |
| Sep 30, 2021 | -309.94% |
| Jun 30, 2021 | 45.98% |